Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan
- PMID: 12141969
- PMCID: PMC2732518
- DOI: 10.3201/eid0805.020014
Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan
Abstract
The rapid emergence (from 0% before 1998 to 6.5% in 2000) of pandrug-resistant Acinetobacter baumannii (PDRAB) was noted in a university hospital in Taiwan. To understand the epidemiology of these isolates, we studied 203 PDRAB isolates, taken from January 1999 to April 2000: 199 from 73 hospitalized patients treated at different clinical settings in the hospital and 4 from environmental sites in an intensive-care unit. Pulsed-field gel electrophoresis analysis and random amplified polymorphic DNA (RAPD) generated by arbitrarily primed polymerase chain reaction of these 203 isolates showed 10 closely related genotypes (10 clones). One (clone 5), belonging to pulsotype E and RAPD pattern 5, predominated (64 isolates, mostly from patients in intensive care). Increasing use of carbapenems and ciprofloxacin (selective pressure) as well as clonal dissemination might have contributed to the wide spread of PDRAB in this hospital.
Figures
Similar articles
-
Genotypic analysis of Acinetobacter bloodstream infection isolates in a Turkish university hospital.Scand J Infect Dis. 2006;38(5):335-40. doi: 10.1080/00365540500488907. Scand J Infect Dis. 2006. PMID: 16709534
-
Molecular characterization and antimicrobial susceptibility of Acinetobacter baumannii isolates obtained from two hospital outbreaks in Los Angeles County, California, USA.BMC Infect Dis. 2016 May 4;16:194. doi: 10.1186/s12879-016-1526-y. BMC Infect Dis. 2016. PMID: 27146090 Free PMC article.
-
Imported and intensive care unit-born Acinetobacter baumannii clonal complexes: one-year prospective cohort study in intensive care patients.Microb Drug Resist. 2013 Jun;19(3):216-23. doi: 10.1089/mdr.2012.0174. Epub 2013 Jan 21. Microb Drug Resist. 2013. PMID: 23336529
-
Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options.Int J Antimicrob Agents. 2012 Feb;39(2):105-14. doi: 10.1016/j.ijantimicag.2011.10.004. Epub 2011 Nov 22. Int J Antimicrob Agents. 2012. PMID: 22113193 Review.
-
[Multidrug resistant Acinetobacter baumannii].Klin Mikrobiol Infekc Lek. 2008 Oct;14(5):162-7. Klin Mikrobiol Infekc Lek. 2008. PMID: 19051163 Review. Czech.
Cited by
-
Acinetobacter baumannii infection in intensive care unit: analysis of distribution and drug resistance.Mol Biol Rep. 2024 Jan 16;51(1):120. doi: 10.1007/s11033-023-09144-3. Mol Biol Rep. 2024. PMID: 38227070
-
Pyopneumothorax caused by Parvimonas micra and Prevotella oralis: a case report.World J Emerg Med. 2023;14(6):488-491. doi: 10.5847/wjem.j.1920-8642.2023.091. World J Emerg Med. 2023. PMID: 37969220 Free PMC article. No abstract available.
-
Acinetobacter baumannii Global Clone-Specific Resistomes Explored in Clinical Isolates Recovered from Egypt.Antibiotics (Basel). 2023 Jul 4;12(7):1149. doi: 10.3390/antibiotics12071149. Antibiotics (Basel). 2023. PMID: 37508245 Free PMC article.
-
The role of nanotechnology-based approaches for clinical infectious diseases and public health.Front Bioeng Biotechnol. 2023 Apr 3;11:1146252. doi: 10.3389/fbioe.2023.1146252. eCollection 2023. Front Bioeng Biotechnol. 2023. PMID: 37077227 Free PMC article. Review.
-
Lipocalin-2 is an essential component of the innate immune response to Acinetobacter baumannii infection.PLoS Pathog. 2022 Sep 2;18(9):e1010809. doi: 10.1371/journal.ppat.1010809. eCollection 2022 Sep. PLoS Pathog. 2022. PMID: 36054235 Free PMC article.
References
-
- Hsueh PR, Chen ML, Sun CC, Chen WH, Pan HJ, Yang LS, et al. Emergence of antimicrobial drug resistance of major pathogens causing nosocomial infections at a university hospital in Taiwan, 1981-1999. Emerg Infect Dis. 2002;8:63–8. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous